MAR 13·Simply Wall St▲
Legend Biotech (LEGN) Is Up 7.3% After CARVYKTI Reaches Profitability And 10,000 Patients Treated
Legend Biotech's stock rose 7.3% after reporting that its CARVYKTI franchise achieved product-level profitability in 2025 and treated over 10,000 patients. The company reported Q4 2025 revenue of US$306.3 million, with CARVYKTI sales reaching approximately US$1.9 billion for the full year. While CARVYKTI is now profitable and expanding, the company still posted a GAAP net loss for the quarter and year, highlighting the ongoing challenge of achieving overall company-wide profitability and diversification beyond this single asset.
JAN 29·Investing.com Australia▼
Legend Biotech stock hits 52-week low at $18.07 By Investing.com
Legend Biotech (LEGN) stock has reached a new 52-week low of $18.07, representing a 49.61% decline over the past year and a 56% drop in the last six months due to broader biotech challenges and an earnings miss for its CARVYKTI product. Despite this, the company maintains a strong financial position with more cash than debt and significant revenue growth, and analysts still see considerable upside potential, with some reiterating Buy ratings based on upcoming clinical milestones and regulatory developments.
